Dacomitinib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 421 publications

Drug-induced paronychia: a disproportionality and time-to-onset pharmacovigilance study using FAERS and JADER.

Drug-induced paronychia: a disproportionality and time-to-onset pharmacovigilance study using FAERS and JADER.

Journal: Cutaneous and ocular toxicology

Published: July 07, 2026

Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study.

Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study.

Journal: Journal of neuro-oncology

Published: February 13, 2026

Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study.

Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study.

Journal: Translational lung cancer research

Published: February 03, 2026

HPD is a copper-binding protein that interacts with DLAT to promote colorectal cancer cuproptosis under copper stress.

HPD is a copper-binding protein that interacts with DLAT to promote colorectal cancer cuproptosis under copper stress.

Journal: Cell reports

Published: January 19, 2026

Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report.

Dacomitinib in Combination with chemotherapy is effective in lung adenocarcinoma with rare EGFR L747P mutation and bone metastases: a case report.

Journal: Frontiers in oncology

Published: December 08, 2025

Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers.

Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers.

Journal: Critical reviews in oncology/hematology

Published: December 07, 2025

From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology.

From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology.

Journal: Journal of cancer prevention

Published: December 01, 2025

Multimodal investigation of dacomitinib-calf thymus DNA binding interaction: insights from spectroscopy, thermodynamics, and in-silico studies.

Multimodal investigation of dacomitinib-calf thymus DNA binding interaction: insights from spectroscopy, thermodynamics, and in-silico studies.

Journal: RSC advances

Published: November 29, 2025

Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis.

Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis.

Journal: Therapeutic advances in medical oncology

Published: November 28, 2025

Network toxicology and bioinformatics reveal potential molecular links between cadmium exposure and pancreatic cancer.

Network toxicology and bioinformatics reveal potential molecular links between cadmium exposure and pancreatic cancer.

Journal: BMC pharmacology & toxicology

Published: November 11, 2025

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma.

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma.

Journal: Molecular oncology

Published: November 03, 2025

Unmasking the common enemy: drug resistance mechanisms across three different EGFR inhibitor generations are associated with co-targetable alterations in extracellular matrix signaling.

Unmasking the common enemy: drug resistance mechanisms across three different EGFR inhibitor generations are associated with co-targetable alterations in extracellular matrix signaling.

Journal: Cell communication and signaling : CCS

Published: October 30, 2025

Showing 1-12 of 421

Last Updated: 09/26/2026